Merkel Cell Carcinoma, Version 1.2018

Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Rachel Blitzblau, Glen M. Bowen, Carlo M. Contreras, Gregory A. Daniels, Roy Decker, Jeffrey M. Farma, Kris Fisher, Brian Gastman, Karthik Ghosh, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Manisha Loss, Daniel D. LydiattJane Messina, Kishwer S. Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D. Schmults, Ashok R. Shaha, Valencia Thomas, Yaohui G. Xu, John A. Zic, Karin G. Hoffmann, Anita M. Engh

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.

Original languageEnglish (US)
Pages (from-to)742-774
Number of pages33
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Merkel Cell Carcinoma
Merkel cell polyomavirus
Radiotherapy
Guidelines
Disease Management
Immunotherapy
Biomarkers
Pathology
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., ... Engh, A. M. (2018). Merkel Cell Carcinoma, Version 1.2018. JNCCN Journal of the National Comprehensive Cancer Network, 16(6), 742-774. https://doi.org/10.6004/jnccn.2018.0055

Merkel Cell Carcinoma, Version 1.2018. / Bichakjian, Christopher K.; Olencki, Thomas; Aasi, Sumaira Z.; Alam, Murad; Andersen, James S.; Blitzblau, Rachel; Bowen, Glen M.; Contreras, Carlo M.; Daniels, Gregory A.; Decker, Roy; Farma, Jeffrey M.; Fisher, Kris; Gastman, Brian; Ghosh, Karthik; Grekin, Roy C.; Grossman, Kenneth; Ho, Alan L.; Lewis, Karl D.; Loss, Manisha; Lydiatt, Daniel D.; Messina, Jane; Nehal, Kishwer S.; Nghiem, Paul; Puzanov, Igor; Schmults, Chrysalyne D.; Shaha, Ashok R.; Thomas, Valencia; Xu, Yaohui G.; Zic, John A.; Hoffmann, Karin G.; Engh, Anita M.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 6, 01.06.2018, p. 742-774.

Research output: Contribution to journalReview article

Bichakjian, CK, Olencki, T, Aasi, SZ, Alam, M, Andersen, JS, Blitzblau, R, Bowen, GM, Contreras, CM, Daniels, GA, Decker, R, Farma, JM, Fisher, K, Gastman, B, Ghosh, K, Grekin, RC, Grossman, K, Ho, AL, Lewis, KD, Loss, M, Lydiatt, DD, Messina, J, Nehal, KS, Nghiem, P, Puzanov, I, Schmults, CD, Shaha, AR, Thomas, V, Xu, YG, Zic, JA, Hoffmann, KG & Engh, AM 2018, 'Merkel Cell Carcinoma, Version 1.2018', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 6, pp. 742-774. https://doi.org/10.6004/jnccn.2018.0055
Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R et al. Merkel Cell Carcinoma, Version 1.2018. JNCCN Journal of the National Comprehensive Cancer Network. 2018 Jun 1;16(6):742-774. https://doi.org/10.6004/jnccn.2018.0055
Bichakjian, Christopher K. ; Olencki, Thomas ; Aasi, Sumaira Z. ; Alam, Murad ; Andersen, James S. ; Blitzblau, Rachel ; Bowen, Glen M. ; Contreras, Carlo M. ; Daniels, Gregory A. ; Decker, Roy ; Farma, Jeffrey M. ; Fisher, Kris ; Gastman, Brian ; Ghosh, Karthik ; Grekin, Roy C. ; Grossman, Kenneth ; Ho, Alan L. ; Lewis, Karl D. ; Loss, Manisha ; Lydiatt, Daniel D. ; Messina, Jane ; Nehal, Kishwer S. ; Nghiem, Paul ; Puzanov, Igor ; Schmults, Chrysalyne D. ; Shaha, Ashok R. ; Thomas, Valencia ; Xu, Yaohui G. ; Zic, John A. ; Hoffmann, Karin G. ; Engh, Anita M. / Merkel Cell Carcinoma, Version 1.2018. In: JNCCN Journal of the National Comprehensive Cancer Network. 2018 ; Vol. 16, No. 6. pp. 742-774.
@article{d6d2b2d3d6f841f1b8d5e77caeeeefa1,
title = "Merkel Cell Carcinoma, Version 1.2018",
abstract = "This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.",
author = "Bichakjian, {Christopher K.} and Thomas Olencki and Aasi, {Sumaira Z.} and Murad Alam and Andersen, {James S.} and Rachel Blitzblau and Bowen, {Glen M.} and Contreras, {Carlo M.} and Daniels, {Gregory A.} and Roy Decker and Farma, {Jeffrey M.} and Kris Fisher and Brian Gastman and Karthik Ghosh and Grekin, {Roy C.} and Kenneth Grossman and Ho, {Alan L.} and Lewis, {Karl D.} and Manisha Loss and Lydiatt, {Daniel D.} and Jane Messina and Nehal, {Kishwer S.} and Paul Nghiem and Igor Puzanov and Schmults, {Chrysalyne D.} and Shaha, {Ashok R.} and Valencia Thomas and Xu, {Yaohui G.} and Zic, {John A.} and Hoffmann, {Karin G.} and Engh, {Anita M.}",
year = "2018",
month = "6",
day = "1",
doi = "10.6004/jnccn.2018.0055",
language = "English (US)",
volume = "16",
pages = "742--774",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "6",

}

TY - JOUR

T1 - Merkel Cell Carcinoma, Version 1.2018

AU - Bichakjian, Christopher K.

AU - Olencki, Thomas

AU - Aasi, Sumaira Z.

AU - Alam, Murad

AU - Andersen, James S.

AU - Blitzblau, Rachel

AU - Bowen, Glen M.

AU - Contreras, Carlo M.

AU - Daniels, Gregory A.

AU - Decker, Roy

AU - Farma, Jeffrey M.

AU - Fisher, Kris

AU - Gastman, Brian

AU - Ghosh, Karthik

AU - Grekin, Roy C.

AU - Grossman, Kenneth

AU - Ho, Alan L.

AU - Lewis, Karl D.

AU - Loss, Manisha

AU - Lydiatt, Daniel D.

AU - Messina, Jane

AU - Nehal, Kishwer S.

AU - Nghiem, Paul

AU - Puzanov, Igor

AU - Schmults, Chrysalyne D.

AU - Shaha, Ashok R.

AU - Thomas, Valencia

AU - Xu, Yaohui G.

AU - Zic, John A.

AU - Hoffmann, Karin G.

AU - Engh, Anita M.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.

AB - This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.

UR - http://www.scopus.com/inward/record.url?scp=85049070555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049070555&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0055

DO - 10.6004/jnccn.2018.0055

M3 - Review article

C2 - 29891526

AN - SCOPUS:85049070555

VL - 16

SP - 742

EP - 774

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 6

ER -